Education
About Us
Working with TipRanks
Follow Us
Calidi Biotherapeutics (CLDI)
:CLDI
CLDI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.20 - $3.89
Previous CloseN/A
Volume567.49K
Average Volume (3M)28.42M
Market Cap
$21.82M
Enterprise Value$11.95M
Total Cash (Recent Filing)$1.24M
Total Debt (Recent Filing)$11.71M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Aug 19, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding34,520,580
10 Day Avg. Volume81,839,080
30 Day Avg. Volume28,417,580
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)2.26
Price to Sales (P/S)0.00
P/FCF Ratio-2.02
Enterprise Value/Market Cap0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.26
Enterprise Value/Ebitda-0.17
Forecast
1Y Price Target
$2.50Price Target Upside303.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Calidi Biotherapeutics News
PremiumMarket News
3 Penny Stocks to Watch Now, 7/10/25
PremiumCompany Announcements
Calidi Biotherapeutics Approves Key Proposals at Annual Meeting
PremiumCompany Announcements
Calidi Biotherapeutics Announces Inducement Offer Agreement
PremiumCompany Announcements
Calidi Biotherapeutics Announces Q1 2025 Financial ResultsBulls Say, Bears Say
Bulls Say
Clinical DataEarly clinical data with a single dose of lead agent CLD-101 showed a near doubling of PFS and OS in some glioma patients.
Regulatory ApprovalThe FDA has cleared Northwestern University’s IND application for Calidi’s NeuroNova (CLD-101).
Bears Say
Financial StabilityGiven the company's financial situation, even after the offering, there appears to be meaningful risk to the company continuing as a going concern.
Options Prices
Currently, No data available
---
Ownership Overview
3.35% Insiders
1.47% Mutual Funds
11.72% Other Institutional Investors
82.45% Public Companies and Individual Investors
CLDI FAQ
What was Calidi Biotherapeutics’s price range in the past 12 months?
Calidi Biotherapeutics lowest stock price was $0.20 and its highest was $3.89 in the past 12 months.
What is Calidi Biotherapeutics’s market cap?
Calidi Biotherapeutics’s market cap is $21.82M.
When is Calidi Biotherapeutics’s upcoming earnings report date?
Calidi Biotherapeutics’s upcoming earnings report date is Aug 19, 2025 which is in 31 days.
How were Calidi Biotherapeutics’s earnings last quarter?
Calidi Biotherapeutics released its earnings results on May 14, 2025. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.18.
Is Calidi Biotherapeutics overvalued?
According to Wall Street analysts Calidi Biotherapeutics’s price is currently Undervalued.
Does Calidi Biotherapeutics pay dividends?
Calidi Biotherapeutics does not currently pay dividends.
What is Calidi Biotherapeutics’s EPS estimate?
Calidi Biotherapeutics’s EPS estimate is -0.11.
How many shares outstanding does Calidi Biotherapeutics have?
Calidi Biotherapeutics has 34,520,580 shares outstanding.
What happened to Calidi Biotherapeutics’s price movement after its last earnings report?
Calidi Biotherapeutics reported an EPS of -$0.18 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5%.
Which hedge fund is a major shareholder of Calidi Biotherapeutics?
Currently, no hedge funds are holding shares in CLDI
Calidi Biotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (303.23% Upside)
$2.50 (303.23% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.7%
Last 30 Days ▲ 23.1%
Last 30 Days ▲ 23.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.44%
12-Months-Change
Fundamentals
Return on Equity
354.78%
Trailing 12-Months
Asset Growth
103.43%
Trailing 12-Months
Company Description
Calidi Biotherapeutics
Calidi Biotherapeutics (CLDI) is a biotechnology company focusing on the development of innovative oncolytic virus-based therapies for cancer treatments. The company leverages proprietary technology platforms to enhance the therapeutic potential of oncolytic viruses, aiming to improve cancer treatment outcomes. Calidi Biotherapeutics operates within the biopharmaceutical sector, with its primary focus on developing immuno-oncology therapies targeting various cancer types.